Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN versus GLEOSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN versus GLEOSTINE.
CYTOXAN vs GLEOSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that crosslinks DNA, leading to cell cycle nonspecific cytotoxicity. It requires hepatic activation by cytochrome P450 enzymes to form active metabolites, primarily phosphoramide mustard.
GLEOSTINE (lomustine) is a nitrosourea alkylating agent that crosslinks DNA and RNA, inhibiting DNA synthesis and repair. It is cell cycle phase-nonspecific.
500-1500 mg/m² IV every 2-4 weeks or 1-5 mg/kg/day PO for 10-14 days.
130 mg/m2 orally every 6 weeks as a single dose; alternatively, 75 mg/m2 orally every 3 weeks.
None Documented
None Documented
Terminal elimination half-life of cyclophosphamide is 3-12 hours (range 2-19 h) in adults; the half-life of active metabolites (e.g., 4-hydroxycyclophosphamide) is approximately 8-10 hours. Half-life is prolonged in hepatic impairment (up to 20 h) and reduced in dose adjustments.
16-48 hours (terminal), with an active metabolite half-life of up to 5 days, requiring dose adjustment for renal impairment
Renal elimination of unchanged cyclophosphamide (5-30%) and metabolites (primarily 4-ketocyclophosphamide and carboxyphosphamide) accounts for approximately 80% of total clearance; fecal excretion is minimal (<5%).
Renal: 60% (as metabolites), Fecal: <5% (unchanged and metabolites), Biliary: minimal
Category C
Category C
Alkylating Agent
Alkylating Agent